Novavax

The WHO rates the overall plague risk in Russia as low, prompting vaccine stocks such as Novavax, Moderna and BioNTech to record short-term price declines. Novavax fell sharply on the NASDAQ, and Moderna and BioNTech also slipped. Analysts view the moves as speculative reactions to headlines and emphasize that the companies' fundamentals have not materially changed; investors should approach short-term trading decisions with caution. » More on finanzen.net

At the Citigroup Biopharma Summit, Novavax announced a strategic shift from a pure COVID vaccine maker to a platform company centered on the adjuvant Matrix‑M. Near‑term drivers are partnerships with Sanofi (up to $200 million in milestones) and Pfizer (a $30 million upfront payment, milestone potential up to $500 million plus royalties). Sanofi has begun shipping NUVAXOVID in the U.S.; Novavax emphasizes gradual market share gains over multiple seasons. At the same time, the company is advancing Matrix‑M research in oncology and a C. difficile candidate, keeping R&D spending lean and viewing the partnerships as the basis for extended financial runway. » More on de.investing.com

Novavax is moving from direct commercialization to a technology-licensing platform and plans to license its saponin-based adjuvant Matrix‑M and nanoparticle protein technology to major pharma partners. The company received $800 million in upfront and milestone payments from Pfizer and Sanofi over the past three years, has identified additional near-term milestones of $200 million, and cut its cost base by 80–90%, extending its financial runway to more than two years. Novavax is targeting non-GAAP profitability in 2028 (requiring revenue > $150 million), sees significant potential for combined COVID‑flu vaccines and expanded oncology applications, and expects multiple upcoming catalysts from partner studies and proof-of-concept data. » More on de.investing.com